{"id":"tri-weekly-cisplatin-with-rt","safety":{"commonSideEffects":[{"rate":"70-80%","effect":"Nausea and vomiting"},{"rate":"40-50%","effect":"Neutropenia"},{"rate":"20-30%","effect":"Kidney dysfunction"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"featherless-qwen","explanation":"Cisplatin forms covalent bonds with DNA, leading to cross-linking and strand breaks, which disrupts DNA replication and transcription, ultimately causing cell death. When combined with radiation therapy (RT), the cytotoxic effects of both treatments are synergistic, enhancing tumor cell kill.","oneSentence":"Cisplatin works by damaging DNA and preventing cancer cells from dividing and growing.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:40:05.264Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Locally advanced head and neck cancer"},{"name":"Locally advanced cervical cancer"}]},"trialDetails":[{"nctId":"NCT04091867","phase":"PHASE1","title":"sEphB4-HSA With RT+Chemo or Cetux in Patients With Intermediate to High Risk LAHNSCC","status":"COMPLETED","sponsor":"University of Colorado, Denver","startDate":"2020-01-06","conditions":"Squamous Cell Carcinoma of Head and Neck","enrollment":3},{"nctId":"NCT02709720","phase":"PHASE2","title":"Study of Vinorelbine and Cisplatin as Induction Therapy With Radiotherapy in Patients With Unresectable NSCLC","status":"COMPLETED","sponsor":"Spanish Lung Cancer Group","startDate":"2016-04-15","conditions":"Lung Cancer","enrollment":68},{"nctId":"NCT01561586","phase":"PHASE3","title":"Tri-weekly Cisplatin Based Chemoradiation in Locally Advanced Cervical Cancer","status":"UNKNOWN","sponsor":"Korea Cancer Center Hospital","startDate":"2012-03","conditions":"Cervical Cancer","enrollment":374}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Cisplatin"],"phase":"phase_3","status":"active","brandName":"Tri-weekly cisplatin with RT","genericName":"Tri-weekly cisplatin with RT","companyName":"Korea Cancer Center Hospital","companyId":"korea-cancer-center-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Tri-weekly cisplatin is used in combination with radiation therapy (RT) for the treatment of certain cancers, including Squamous Cell Carcinoma of the Head and Neck, Lung Cancer, and Cervical Cancer. This treatment combination is being studied in clinical trials, such as NCT04091867, which is evaluating the efficacy of sEphB4-HSA with RT and chemotherapy or cetuximab in patients with intermediate to high risk LAHNSCC.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}